Proveca Go Green for World Cerebral Palsy Day

World Cerebral Palsy Day is celebrated on Saturday 6th October 2018. The main aims of the day are to raise awareness of cerebral palsy. To ensure that children and adults with cerebral palsy are not discriminated against and receive the same rights and opportunities as the rest of our society, and also to celebrate the lives and achievements of those both who suffer from cerebral palsy and the individuals and organisations who support them.

Cerebral palsy is a lifelong disability affecting around 17 million people throughout the world. At this time there is no known cure. It is a complex disability that can vary in effect from one individual to another with symptoms ranging from weakness in one hand to a complete lack of voluntary movement throughout the body.

Staff at Proveca are going to wear something green in support of this day #gogreenforcp


Launches in European Markets

We are delighted to announce that Sialanar, licenced throughout Europe as a Paediatric Use Marketing Authorisation (PUMA), has been granted full reimbursement from the Swedish Pricing and Reimbursement authority and is now available in Sweden, Denmark and Norway via our partner Anthrop Pharmaceuticals AB  ( 

Sialanar is also available in Germany and Ireland. Future launches in other European countries will be announced in due course. 



Proveca Hold their Second Paediatric Educational Meeting in Birmingham

Proveca held their second paediatric educational meeting at the Birmingham Children’s Hospital on 4th of July.  The programme was titled ‘Hypersalivation in Cerebral Palsy – A problem that should be taken seriously and licensed versus unlicensed medication in children.'

Professor Rajat Gupta, Lead Consultant in Paediatric Neurology, Birmingham Children’s Hospital, presented on Hypersalivation in Cerebral Palsy – A problem that should be taken seriously.  Dr Helen Shaw, Medical Director, Proveca, gave an overview of the pan-European approach to licensing off-patent medicines in children, the Paediatric Use Marketing Authorisation (PUMA) and finally Mr Yusuf Asif, Clinical Formulary Pharmacist, Birmingham Children’s Hospital presented on licensed versus unlicensed medication in children.  Dr Manjeet Raina, Consultant in Paediatric Neurodisability from Heartlands Birmingham Community Healthcare Trust chaired the meeting which was attended by many Paediatric Consultants from around Birmingham and the Midlands. 

The meeting was an enormous success with excellent feedback including:

’Thorough discussion on drooling and impact on quality of patients’ lives and social status’

‘Helpful to know about pharmaceutical issues associated with unlicensed medications, very helpful, nice explanation why we should use licensed medicationss where possible’

'Clear and informative delivery of presentations from all 3 speakers'